Over the past five decades, a marked shift in the number of women practicing gynecologic oncology has transformed the field. The specialty began as 57 men gynecologists, who saw an unmet need in the care of women with malignancies of the female genital tract.
The rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1RAs), particularly for weight management, represents one of the most significant shifts in metabolic medicine in decades. With millions of people now using medications such as semaglutide and tirzepatide, we are witnessing a fundamental alteration in patient physiology that extends far beyond glucose control and weight loss. As these drugs approach 10% population penetrance in some demographics, the oncology community faces an urgent question: How will this metabolic transformation reshape cancer care?
